A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Why is the amber Study Being Done?
TSR-022 is an investigational immunotherapy drug called an anti-TIM-3. The trial will look at how safe and effective TSR-022 is by itself and together with another investigational immunotherapy drug, called an anti-PD-1 antibody.
- Advanced or metastatic solid tumor with disease progression after treatment with available therapies (or not able to tolerate treatment).
- Women who are able to become pregnant must have a negative serum pregnancy test within 72 hours before the date of the first dose of study medication.
- Prior therapy with an anti-PD-1, an anti-PD-L1, or an anti-PD- L2 agent.
- Patient experienced >/= Grade 3 immune-related adverse event with prior immunotherapy, with the exception of non-clinically-significant lab abnormalities.
- History of HIV, certain lung diseases, or active Hepatitis B or Hepatitis C.
How do I Know if the Amber Trial is Right for Me?
The best next step is to contact the research site that would be the most convenient for you in order to discuss your medical history and whether the AMBER clinical trial would be a good fit.
To find sites in your area, contact: firstname.lastname@example.org or use the form above.
To find additional information on AMBER see: clinicaltrials.gov